Regenerex Pharma (RGPX) Cash & Equivalents (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Cash & Equivalents data on file, last reported at $11659.0 in Q3 2025.

• Cash & Equivalents for Q3 2025 came in at $11659.0, up 3865.65% year-over-year; the trailing twelve-month figure through Sep 2025 was $11659.0 (up 3865.65% YoY), and the FY2025 annual result was $653025.0, up 175444.35% from the prior year.
• Cash & Equivalents declined to $11659.0 in Q3 2025 per RGPX's latest filing, from $172430.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $653025.0 in Q1 2025 and troughed at $294.0 in Q3 2024.
• A 5-year average of $52515.4 and a median of $2714.5 in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 95.7% in 2024, then surged 175444.35% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $2789.0 in 2021, then slumped by 56.87% to $1203.0 in 2022, then surged by 553.03% to $7856.0 in 2023, then slumped by 95.7% to $338.0 in 2024, then jumped by 3349.41% to $11659.0 in 2025.
• Business Quant data shows RGPX's Cash & Equivalents at $11659.0 in Q3 2025, $172430.0 in Q2 2025, and $653025.0 in Q1 2025.